OLMA insider sells 15,000 shares for $345K

Shawnte M. Mitchell reported insider transactions related to common stock of the issuer.

Rhea-AI Filing Summary

Shawnte M. Mitchell reported insider transactions related to common stock of the issuer. The filing shows a sale of 15,000 common shares on 03/03/2026 for $345,153. It also lists a proposed sale of 25,000 common shares through Fidelity Brokerage Services LLC on 03/04/2026, arising from an option granted on 02/28/2025, to be sold for cash.

Insights

Corporate Governance / Insider Transactions

Insider reported a recent sale and a separate proposed sale tied to a prior option grant.

The filing documents a completed sale of $345,153 for 15,000 common shares on 03/03/2026

It also lists a planned disposition of 25,000 common shares through Fidelity Brokerage Services LLC on 03/04/2026, linked to an option granted on 02/28/2025. Cash is listed as the consideration. Timing and settlement details beyond the dates shown are not disclosed in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions does OLMA's Form 144 report show?

The filing reports a sale of 15,000 common shares on 03/03/2026 for $345,153, and a proposed sale of 25,000 common shares scheduled on 03/04/2026 tied to an option granted 02/28/2025.

Who is the reporting person in the OLMA Form 144 filing?

The reported filer is Shawnte M. Mitchell, with an address shown in San Francisco. The filing lists both the recent 15,000-share sale and the planned 25,000-share disposition through Fidelity Brokerage Services LLC.

What broker or intermediary is named for the planned OLMA sale?

The planned sale lists Fidelity Brokerage Services LLC as the broker, with the transaction showing 25,000 shares and an execution date of 03/04/2026, and the payment method indicated as cash.

Was the proposed sale in OLMA tied to an option or grant?

Yes. The filing indicates the proposed sale of 25,000 common shares is linked to an option granted on 02/28/2025, with the planned sale date listed as 03/04/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 10:21 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001749432
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Olema Pharmaceuticals, Inc.
SEC File Number	001-39712
Address of Issuer	780 BRANNAN STREET SAN FRANCISCO CALIFORNIA 94103
Phone	(415) 651-3316
Name of Person for Whose Account the Securities are To Be Sold	Mitchell Shawnte
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	25000	598500.00	68659923	03/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/04/2026	Option Granted - 02/28/2025	Issuer			25000	03/04/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shawnte M. Mitchell 780 Brannan Street San Francisco CA 94103	Common	03/03/2026	15000	345153.00

144: Remarks and Signature

Remarks
Date of Notice	03/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Shawnte M. Mitchell
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)